MArcila

@MEArcila

Manhattan, NY

Joined April 2018

85 Following

48 Followers

5 Posts

MArcila @MEArcila

about 3 years ago

@SeanLachhander Amazing! my best wishes to you both.

MArcila @MEArcila

over 3 years ago

Featured today by @MSKLibrary: Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therap... https://t.co/YAgt2LDF84

MArcila @MEArcila

about 4 years ago

Featured today by @MSKLibrary: Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomi... https://t.co/4nQ8fK4dao

MArcila @MEArcila

about 5 years ago

@CancerCytopath Yes - very feasible. We recently also published our experience with 300+ cytology samples - outlining that with proper handling, these samples are sufficient for ultra-rapid mutation screening and reflex comprehensive NGS.

MEArcila's tweet photo. @CancerCytopath Yes - very feasible. We recently also published our experience with 300+ cytology samples - outlining that with proper handling, these samples are sufficient for ultra-rapid mutation screening and reflex comprehensive NGS. https://t.co/5uWtUoNziQ

Who to follow

Raffaele Califano

@caliraf

Thoracic Oncologist @TheChristieNHS, Honorary Professor @UoM_DCS . Member @myesmo Educational Publication WG. Views are my own No DMs or medical advice given.

Ahmet Zehir

@ahmetz

VP, Bioinformatics @ Natera. Crossfitter, photographer, baker, potter. He, him. 🏳️‍🌈 (Tweets and views are all mine)

Fernanda Sábato

@FernandaSabato

Clinical Biochemist, Molecular Pathology Scientist, Educator. Love for swimming, sewing and design.

MEArcila retweeted

Jackie Hechtman @JackieHechtman

about 6 years ago

Testing for kinase fusions is of particular value after resistance to endocrine therapy emerges if ESR1 is wild type as it opens another avenue for treatment. We did find (rare) kinase fusions in endocrine therapy- naive tumors as well!

MArcila

@MEArcila

Who to follow

Last Seen Users on Sotwe

Trends for you

Most Popular Users